Cancer Supportive Care

Global Market Trajectory & Analytics

MCP10866

EXECUTIVE ENGAGEMENTS

POOL

3853
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

694
Interactions with Platform & by Email

PARTICIPANTS

116
Unique # Participated

VALIDATIONS

33
Responses Validated*

COMPANIES

16
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

66

PAGES

112

EDITION

6

PRICE

USD 4950

CODE

MCP10866


COMPETITIVE METRICS

COMPANY

D S N T

% *

Acacia Pharma Group Plc

Login Required

Amgen, Inc.

Login Required

Biomodels

Login Required

Biovitrum

Login Required

Celgene Corporation

Login Required

Chroma Group, Inc.

Login Required

Eldercare Home Health Inc.

Login Required

F. Hoffmann-La Roche AG

Login Required

GlaxoSmithKline PLC

Login Required

Helsinn Healthcare SA

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 16 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Cancer Supportive Care estimated at US$21.7 Billion in the year 2020, is projected to reach a revised size of US$24.6 Billion by 2027, growing at a CAGR of 1.8% over the analysis period 2020-2027. G-CSFs, one of the segments analyzed in the report, is projected to record a 1.3% CAGR and reach US$5.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bisphosphonates segment is readjusted to a revised 2.2% CAGR for the next 7-year period.
The Cancer Supportive Care market in the U.S. is estimated at US$6.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2027 trailing a CAGR of 1.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.7% and 1.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.
In the global Antiemetics segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.8 Billion by the year 2027.

SELECT PLAYERS

Amgen, Inc.; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Helsinn Healthcare SA; Heron Therapeutics, Inc.; Johnson & Johnson; Kyowa Hakko Kirin Co., Ltd.; Merck & Co., Inc.; Novartis AG; Tesaro, Inc.; Teva Pharmaceutical Industries Ltd.

SEGMENTS

» Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for G-CSFs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Antiemetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for ESAs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
Total Companies Profiled: 16

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com